NIH Highlighted Topic: Advanced Biomaterials for Biomedical Research
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research on advanced biomaterials that overcome a core limitation of today's research tools: traditional biomaterials fail to recapitulate the tissue complexity, heterogeneity, and dynamic change seen in living systems. This highlighted topic seeks new materials that let material scientists and biomedical researchers work together to solve fundamental biological problems.
NIH is particularly interested in biomaterials that enable dynamic physical properties, detect and respond to tissue-specific changes, behave in robust and predictable ways, and improve reproducibility in disease models. Multidisciplinary teams that combine materials scientists, physical scientists, bioengineers, and biomedical researchers are strongly encouraged.
Areas of interest include responsive and programmable biomaterials (pH, thermal, light, electrostatic, and stiffness responsive), functionalized materials that model the transition from normal tissue to tumor microenvironment, biomaterials that modulate immune, nerve, vascular, or lymphatic components, and approaches that pair material science with synthetic biology to study cancer.
How to apply: This is a Highlighted Topic rather than a standalone NOFO, so it has no dedicated solicitation or deadline of its own. Small businesses should apply through the NIH SBIR omnibus (PA-27-100) or STTR omnibus (PA-27-102) and reference this Highlighted Topic by name in the Specific Aims or Significance section so program staff can connect the application to this priority. STTR is a natural fit for company and university materials science partnerships. We also recommend contacting the listed NCI or NIDCR scientific contact to confirm fit before writing.
This highlighted topic is supported by the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR). NIDCR notes it may give special consideration to meritorious applications in this area. The topic is active from September 9, 2026 through September 9, 2028.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of advanced biomaterials, engineered tissue models, and enabling research tools that more faithfully reproduce living tissue.
Eligible activities may include:
Stimuli-responsive and programmable hydrogels, scaffolds, and matrices
Materials with tunable stiffness, porosity, and degradation for disease modeling
Engineered tumor microenvironment models for cancer research and drug testing
Biomaterials that incorporate immune, vascular, lymphatic, or nerve components
Material platforms combined with synthetic biology and engineered cells
Embedded sensing materials that detect and report tissue-specific changes
Dental, oral, and craniofacial biomaterials and tissue models
Standardized, reproducible biomaterial kits for research laboratories
Scale-up and manufacturing process development for research-grade materials
Characterization, quality control, and validation studies
Prototype development and usability testing with research end users
Commercialization planning and market validation
Funding may also support personnel, materials and supplies, equipment, contract research, academic collaborations, intellectual property protection, and commercialization activities necessary to advance a scalable and commercially viable biomaterial product aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. The next standard deadline is January 5, 2027. This Highlighted Topic remains active until September 9, 2028. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have 500 or fewer employees including affiliates.
Are more than 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute's specific research mission, including an explicit connection to this Highlighted Topic.
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120 to 200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50 to 80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.